The serum of patients with SLE contains high levels of immune complexes that activate platelets via recognition of the immunoglobulin receptor FcγRIIA, a process that has been described as a major driver of platelet activation in patients with SLE [9, 10]. Here, MPIG6B is linked to systemic lupus erythematosus.